Metrics as of 10/14/2026, 12:28 PM (Berlin time), refresh in progress.
NeuroPace Stock
NeuroPace, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Joel D. Becker
- Employees
- 220
- Market cap
- $432 M
- IPO
- 22/04/2021
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical…
NeuroPace stock: price history
1D
-2.5%
1W
+0.1%
1M
-9.7%
6M
-17.4%
YTD
-17.9%
1Y
+21.0%
2Y
+91.8%
5Y
-24.1%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~55% stronger price swings than usual
Ask the agents about NeuroPace
Analyst assessment of NeuroPace
PRICE TARGET LOW
US$18.00
CONSENSUS
US$20.25
MEDIAN
US$20.50
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
9
BUY
1
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 29/07/2026
NeuroPace stock metrics
P/E
-22.18
P/B
36.39
EV/EBITDA
-42.87
RETURN ON EQUITY
-52.2%
NET MARGIN
-27.2%
DEBT/EQUITY
5.88
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.3%
FLOAT SHARES
23,292,847
AVG. DAILY VOLUME (30D)
125,767
Insider transactions (SEC)
Morrell Martha
Williams Patrick F.
Becker Joel
Becker Joel
Morrell Martha
Institutional holders
Comparable stocks
Frequently asked questions about NeuroPace stock
What does NeuroPace do?
NeuroPace, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Joel D. Becker, the company employs around 220 people.
The IPO was on 22/04/2021; the stock trades on NASDAQ under the ticker NPCE.
What do analysts say about NeuroPace stock?
10 analysts rate the stock, the consensus is Buy (as of 29/07/2026).
The average price target is US$20.25, ranging from US$18.00 to US$22.00, with a median of US$20.50.
This is an external assessment, not a statement by Market Jury.
When does NeuroPace report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 55% stronger than usual.
Does NeuroPace pay a dividend?
No, NeuroPace currently does not pay a dividend.
Which stocks are comparable to NeuroPace?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get NeuroPace stock analyzed?
Clicking "Analyze stock" lets five strategies assess NeuroPace against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.